Eikon Therapeutics, Inc.
EIKN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001861123
In the last 90 days, Eikon Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 77 institutions reported holding it in 13F filings for Q2 2026, worth $344.1M in total; no superinvestor holds it.
Holders of 5% or more of EIKN
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Eikon Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Column Group IV GP, LP | 13D | 11.60%6.35M shares | New | Feb 12, 20261 filing | Feb 12, 2026 | SEC |
| FMR LLC | 13G/A | 9.20%4.99M shares | +2.10 ppfrom 7.10% | May 6, 20262 filings | Aug 6, 2026 | SEC |
| Foresite Capital Fund IV, L.P. | 13G | 7.70%4.15M shares | New | Feb 11, 20261 filing | Feb 11, 2026 | SEC |
| BlackRock Portfolio Management LLC | 13G | 5.50%3.00M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
| Perlmutter Roger M | 13G | 5.20%2.89M shares | New | May 13, 20261 filing | May 13, 2026 | SEC |
| Abu Dhabi Investment Authority | 13G | 5.20%2.82M shares | New | Feb 18, 20261 filing | Feb 18, 2026 | SEC |
| Innovation Endeavors III LP | 13G | 5.00%2.72M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
8 Schedule 13D and 13G filings on Eikon Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 6, 202610:20 AM ET | FMR LLCand 1 other | 13G/A | 9.20%4.99M shares | +2.10 ppfrom 7.10% | Jun 30, 2026 | SEC |
| May 15, 20264:18 PM ET | Innovation Endeavors III LPand 5 others | 13G | 5.00%2.72M shares | New | Mar 31, 2026 | SEC |
| May 13, 20265:24 PM ET | Perlmutter Roger M | 13G | 5.20%2.89M shares | New | Feb 4, 2026 | SEC |
| May 6, 202611:13 AM ET | FMR LLCand 1 other | 13G | 7.10%3.84M shares | New | Mar 31, 2026 | SEC |
| Apr 29, 20264:08 PM ET | BlackRock Portfolio Management LLC | 13G | 5.50%3.00M shares | New | Mar 31, 2026 | SEC |
| Feb 18, 20264:16 PM ET | Abu Dhabi Investment Authorityand 1 other | 13G | 5.20%2.82M shares | New | Feb 4, 2026 | SEC |
| Feb 12, 20266:48 PM ET | Column Group IV GP, LPand 7 others | 13D | 11.60%6.35M shares | New | Feb 6, 2026 | SEC |
| Feb 11, 20264:08 PM ET | Foresite Capital Fund IV, L.P.and 8 others | 13G | 7.70%4.15M shares | New | Feb 4, 2026 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Eikon Therapeutics, Inc. shares.
No Form 144 notices for Eikon Therapeutics, Inc. are on file.